Naxifylline | 166374-49-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: Naxifylline
• 英文别名: 8-[(1S,2R,4S,5S,6S)-3-oxatricyclo[3.2.1.02,4]octan-6-yl]-1,3-dipropyl-7H-purine-2,6-dione
• CAS: 166374-49-8
• 化学式: C₁₈H₂₄N₄O₃
• 分子量: 344.4
• InChiKey: OQCJPFYWFGUHIN-GJKBLCTNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.72
• 拓扑面积：
  81.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  8-(1R,2R,4R)-Bicyclo[2.2.1]hept-5-en-2-yl-1,3-dipropyl-3,9-dihydro-purine-2,6-dione 以66的产率得到Naxifylline
  参考文献：
  名称：

  J. Med. Chem. 1997, 40, 1773-1778

  摘要：

  DOI：

文献信息

• BETA ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS
  申请人：RICKLES Richard

  公开号：US20100009934A1

  公开（公告）日：2010-01-14

  The invention features a method of treating a B-cell proliferative disorder by administering to a patient a BAR agonist, e.g., formulated for administration by a route other than inhalation (such as for oral or intravenous administration), in an amount effective to treat the B-cell proliferative disorder. The BAR agonist may be administered as a monotherapy or in combination with one or more other agents, e.g., a PDE inhibitor, an A2A receptor agonist, or an antiproliferative compound, in amounts that together are effective to treat the B-cell proliferative disorder. The invention further features pharmaceutical compositions and kits including a BAR agonist, alone or in combination with additional agents, for the treatment of a B-cell proliferative disorder.
• J. Med. Chem. 1997, 40, 1773-1778
  作者：

  DOI：——

  日期：——